S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CNCR

Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$16.48
$16.78
50-Day Range
$27.45
$32.25
52-Week Range
$25.99
$35.82
Volume
12,378 shs
Average Volume
6,668 shs
Market Capitalization
$14.96 million
Assets Under Management
$23.57 million
Dividend Yield
1.74%
Net Expense Ratio
0.79%

About Range Cancer Therapeutics ETF

The Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.

CNCR ETF News Headlines

Microbix Unveils Test Controls for Head and Neck Cancer
AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
ETF S.S.-LONCAR CAN.I.ETF (E18B.BE)
AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
See More Headlines
Receive CNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
Exchange Traded Concepts
Fund Name
Range Cancer Therapeutics ETF
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:CNCR
Inception Date
10/13/2015
Fund Manager
Denise M. Krisko
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
Range Cancer Therapeutics Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
80

Fund Statistics

Assets Under Management
$23.57 million
Average Daily Volume
$73,498.30
Discount/Premium
-0.02%

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Exchange Traded Concepts, LLC
Custodian
U.S. Bank, N.A.
Distributor
Quasar Distributors, LLC
Transfer Agent
U.S. Bank, N.A.
Trustee
N/A
Lead Market Maker
Jane Street

Options

Optionable
N/A
Short Interest
68,300 shs

Miscellaneous

Beta
0.90
Creation Unit
50,000
Creation Fee
$150.00
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Range Cancer Therapeutics ETF Expenses

TypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.79%0.57%0.54%0.48%0.51%
Other Expenses0.00%0.40%0.54%0.32%0.58%
Total Expense0.79%0.72%0.70%0.57%0.70%
Fee Waiver0.00%-0.53%-0.54%-0.20%-0.56%
Net Expense0.79%0.61%0.60%0.54%0.58%

Range Cancer Therapeutics ETF (CNCR) Holdings & Exposure


CNCR ETF - Frequently Asked Questions

Are investors shorting Range Cancer Therapeutics ETF?

Range Cancer Therapeutics ETF saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 68,300 shares, an increase of 73.4% from the February 29th total of 39,400 shares. Based on an average trading volume of 32,600 shares, the days-to-cover ratio is currently 2.1 days.
View Range Cancer Therapeutics ETF's Short Interest
.

What does CNCR invest in?

Range Cancer Therapeutics ETF is a equity fund issued by Exchange Traded Concepts. CNCR focuses on health care investments and follows the Range Cancer Therapeutics Index. The fund's investments total to approximately $23.57 million assets under management.

What stocks does Range Cancer Therapeutics ETF hold?
What is the management fee for Range Cancer Therapeutics ETF?

Range Cancer Therapeutics ETF's management fee is 0.79% and has no other recorded expenses or fee waivers. The net expense ratio for CNCR is 0.79%.

What other stocks do shareholders of Range Cancer Therapeutics ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Range Cancer Therapeutics ETF investors own include Micron Technology (MU), Intel (INTC), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA), Abbott Laboratories (ABT), Alibaba Group (BABA) and Quest Diagnostics (DGX).

Who are Range Cancer Therapeutics ETF's major shareholders?

Range Cancer Therapeutics ETF's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include OLD Mission Capital LLC (1.81%).

This page (NASDAQ:CNCR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners